Short Communication

Zinc deficiency in patients with chronic liver disease in Japan

Itaru Ozeki, Tomohiro Arakawa, Hirokazu Suii, Ryoji Tatsumi, Masakatsu Yamaguchi, Tomoaki Nakajima, Yasuaki Kuwata and Joji Toyota

Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan

Aim: This study aimed to determine the distributions of serum zinc levels and the prevalence of zinc deficiency in patients with chronic liver disease (CLD) in actual clinical practice, and to analyze the association between serum zinc levels and clinical characteristics.

Methods: This study analyzed 1973 patients with CLD, including 749 with liver cirrhosis, who were admitted to Sapporo Kosei General Hospital in 2017.

Results: Zinc deficiency, defined as a serum zinc level of <60 μg/dL, was observed in 555 patients overall (28.1%), including 182 (14.9%) patients without liver cirrhosis and 373 (49.8%) with liver cirrhosis. When marginal zinc deficiency was included, zinc deficiency (serum zinc level <80 μg/dL) was observed in 1594 (80.8%) patients overall, including 924 (75.5%) patients without liver cirrhosis and 670 (89.5%) with liver cirrhosis. Serum zinc levels were most strongly correlated with serum albumin levels. Of the 257 CLD patients with an albumin level of <3.5 g/dL, 234 (91.1%) had a serum zinc level of <60 μg/dL.

Conclusions: Zinc deficiency is common in patients with CLD. Serum zinc levels should be regularly measured, particularly in patients with liver cirrhosis.

Key words: chronic liver diseases, liver cirrhosis, zinc

INTRODUCTION

ZINC ACTS AS an active center of or coenzyme for >300 types of enzymes to mediate DNA synthesis, RNA transcription, cell growth and division, and other processes including synthesis, regeneration, and protein maintenance in the body. Currently, zinc is considered an essential trace element for maintaining life.1-4

In 2002, the World Health Organization stated that zinc deficiency is one of the most important risk factors for morbidity and mortality in developing countries.5 A subsequent survey showed that zinc deficiency affects 17.3% of the global population, and that Japan has the highest prevalence (15-25%) among developed countries.6 Diseases that cause zinc deficiency in adults include chronic liver disease (CLD), inflammatory bowel disease, short bowel syndrome, renal diseases including conditions requiring dialysis, and diabetes mellitus.7 In CLDs, a decreased capacity to synthesize albumin, the malabsorption of zinc from the intestine, and increased zinc excretion in the urine cause zinc deficiency.8-10 Although zinc deficiency and CLDs are closely associated as described above, no previous large-scale studies have investigated the reality of zinc deficiency. The present study aimed to determine the distributions of serum zinc levels and the prevalence of zinc deficiency in patients with CLD in actual clinical practice, and to analyze the association between serum zinc levels and clinical characteristics.

METHODS

Patients

We measured serum zinc levels and analyzed the association between patient characteristics and blood test values in 1973 patients with CLD who were admitted to Sapporo Kosei General Hospital between January and December 2017. Although patients with CLD were defined as those with an identified cause of liver dysfunction who could be regularly followed up for at least 6 months, patients in whom the cause was not identified or was only suspected were classified as those with unknown causes. We concluded there was diagnosable alcoholic liver disease in patients whose daily ethanol consumption was >60g/day. Non-alcoholic fatty liver disease
was diagnosed according to the Practice Guideline by the American Association for the Study of Liver Diseases. Liver cirrhosis was diagnosed based on liver histology, transient elastography (liver stiffness of $\geq 14.5$ kPa measured with Fibroscan), or the presence of gastroesophageal varices. Patients treated with oral polaprezinc and zinc acetate hydrate, and those with acute hepatitis were excluded. The use of the following concomitant drugs was examined: enteral branched-chain amino acid (BCAA)-enriched nutrient mixtures, BCAA granules, non-absorbable disaccharides, non-absorbable antibiotics, and diuretics. The study protocol conformed to the 1975 Declaration of Helsinki, and was approved by the ethics committees of our institutions.

**Measurement of the plasma concentration of zinc and definitions of zinc deficiency**

The plasma concentration of zinc was assessed using an atomic absorption spectrophotometer (Hitachi High-Tech Science, Tokyo, Japan). According to the 2016 Practice Guidelines for Zinc Deficiency issued by the Japanese Society of Clinical Nutrition, zinc deficiency was defined as a zinc level of $< 60$ μg/dL; marginal zinc deficiency was defined as a zinc level of $\geq 60$ and $< 80$ μg/dL.

**Statistical analysis**

Descriptive statistics are reported as a proportion (%) for categorical variables, and as the mean ± SD for continuous variables. Frequency comparisons between groups were analyzed using the $\chi^2$-test. The Mann–Whitney $U$-test was used to analyze continuous data. Spearman’s rank correlation coefficient analysis was used to evaluate relationships between serum zinc levels and blood test values and patients’ clinical characteristics. A $P$-value of $< 0.05$ was considered statistically significant. Statistical analyses were carried out with R (http://www.r-project.org/).

**RESULTS**

**Patients’ clinical characteristics**

The mean patient age was 66 years, and there were 1017 men (51.5%). The present study included 477 patients with a treatment history of hepatocellular carcinoma (HCC; 24.2%), 270 with a treatment history of gastroesophageal varices (13.7%), 57 with a treatment history of hepatic encephalopathy (2.9%), and 121 with ascites (6.1%). Compared with patients without cirrhosis, the patients with cirrhosis were older, predominately male, and had a higher body mass index. The patients with cirrhosis were more likely to have diabetes; a treatment history of HCC, gastroesophageal varices, or hepatic encephalopathy; and ascites. A total of 682 (34.6%) patients with chronic hepatitis C, 681 (34.5%) with chronic hepatitis B, 194 (9.8%) with alcoholic liver disease, 193 (9.8%) with non-alcoholic fatty liver disease, 51 (2.6%) with autoimmune hepatitis, 43 (2.2%) with primary biliary cholangitis, and 100 (5.1%) with unknown causes had underlying etiology. The prevalence of chronic hepatitis B was significantly higher in patients without cirrhosis than in those with cirrhosis. By contrast, compared with patients without cirrhosis, patients with cirrhosis were significantly more likely to have alcoholic liver disease, non-alcoholic fatty liver disease, others, and unknown etiology. All concomitant drugs were more frequently used in patients with cirrhosis. Blood test results showed significant differences between patients with and without cirrhosis for all parameters, except for glycated hemoglobin and serum iron (Table 1).

**Distributions of serum zinc levels**

Overall, the serum zinc levels were $< 40$ μg/dL in 87 patients (4.4%), $\geq 40$ to $< 60$ μg/dL in 468 patients (23.7%), $\geq 60$ to $< 80$ μg/dL in 1039 patients (52.7%), and $\geq 80$ μg/dL in 379 patients (19.2%). In total, 1224 patients without cirrhosis were divided into the same categories, which included 84 (0.2%), 179 (14.6%), 742 (60.6%), and 300 (24.5%) patients, respectively. Furthermore, 749 patients with cirrhosis were divided into the same categories, which included 84 (11.2%), 289 (38.6%), 297 (39.7%), and 79 (10.5%) patients, respectively. Zinc deficiency was observed in 555 patients overall (28.1%), including 182 (14.9%) patients without cirrhosis and 373 (49.8%) with cirrhosis. When marginal zinc deficiency was included, zinc deficiency (serum zinc level $< 80$ μg/dL) was observed in 1594 (80.8%) patients overall, including 924 (75.5%) patients without cirrhosis and 670 (89.5%) with cirrhosis (Fig. 1). The mean serum zinc levels were 66.9 μg/dL (SD 11.5 μg/dL) overall, 71.6 μg/dL (SD 9.4 μg/dL) in patients without cirrhosis, and 59.3 μg/dL (SD 12.7 μg/dL) in patients with cirrhosis.

**Correlation of serum zinc levels with blood test values and patients’ clinical characteristics**

Serum zinc levels were moderately correlated with serum albumin, cholinesterase, Mac-2 binding protein glycosylation isomer (M2BPGi), FIB-4 index, and hemoglobin levels; they were weakly correlated with total cholesterol, prothrombin, ammonia, platelet, serum alkaline phosphatase (ALP), serum alanine aminotransferase levels; BCAA/tyrosine ratio; and age. When only the patients with cirrhosis were considered, the serum zinc levels were strongly correlated with albumin and cholinesterase levels,
Table 1 Patients’ characteristics

|                               | Overall (n = 1973) | Non-cirrhosis (n = 1224) | Cirrhosis (n = 749) | P-value   |
|-------------------------------|--------------------|--------------------------|---------------------|-----------|
| Age (years)                   | 66 (9)             | 64 (9)                   | 70 (10)             | <0.001    |
| Sex (male)                    | 1017 (51.5)        | 565 (46.2)               | 452 (60.3)          | <0.001    |
| Height (cm)                   | 160.0 (7.8)        | 160.3 (7.7)              | 159.6 (8.0)         | 0.416     |
| Body weight (kg)              | 61.1 (10.2)        | 60.8 (10.3)              | 61.5 (10.1)         | 0.191     |
| BMI (kg/m²)                   | 23.8 (3.1)         | 23.6 (3.1)               | 24.0 (3.2)          | 0.021     |
| Diabetes mellitus             | 245 (12.4)         | 100 (8.2)                | 145 (19.4)          | <0.001    |
| Treatment history of HCC      | 477 (24.2)         | 155 (12.7)               | 322 (43.0)          | <0.001    |
| Treatment history of varices  | 270 (13.7)         | 11 (0.9)                 | 259 (34.6)          | <0.001    |
| Treatment history of encephalopathy | 57 (2.9)   | 2 (0.2)                  | 55 (7.3)            | <0.001    |
| Present of ascites            | 121 (6.1)          | 0 (0)                    | 121 (16.2)          | <0.001    |
| Etiology                      |                    |                          |                     |           |
| HCV                           | 682 (34.6)         | 435 (35.5)               | 247 (33.0)          | 0.246     |
| HBV                           | 681 (34.5)         | 517 (42.2)               | 164 (21.9)          | <0.001    |
| Alcoholic liver disease       | 194 (9.8)          | 52 (4.2)                 | 142 (19.0)          | <0.001    |
| Non-alcoholic fatty liver disease | 193 (9.8)    | 107 (8.7)                | 86 (11.5)           | 0.047     |
| AIH                           | 51 (2.6)           | 36 (2.9)                 | 15 (2.0)            | 0.202     |
| PBC                           | 43 (2.2)           | 27 (2.2)                 | 16 (2.1)            | 0.918     |
| Others†                       | 29 (1.5)           | 9 (0.7)                  | 20 (2.7)            | 0.001     |
| Unknown                       | 100 (5.1)          | 41 (3.3)                 | 59 (7.9)            | <0.001    |
| Dosing                        |                    |                          |                     |           |
| Diuretics                     | 269 (13.6)         | 24 (2.0)                 | 245 (32.7)          | <0.001    |
| Non-absorbable disaccharides  | 131 (6.6)          | 5 (0.4)                  | 126 (16.8)          | <0.001    |
| Non-absorbable antibiotics    | 92 (4.7)           | 1 (0.1)                  | 91 (12.1)           | <0.001    |
| BCAA-enriched nutrient        | 147 (7.5)          | 5 (0.4)                  | 142 (19.0)          | <0.001    |
| BCAA granules                 | 222 (11.2)         | 24 (2.0)                 | 198 (26.4)          | <0.001    |
| WBC (×10⁹/μL)                 | 4.7 (1.2)          | 5.0 (1.2)                | 4.3 (1.2)           | <0.001    |
| Hemoglobin (g/dL)             | 12.8 (1.4)         | 13.2 (1.1)               | 12.1 (1.7)          | <0.001    |
| Platelets count (×10⁹/μL)     | 13.7 (4.7)         | 16.2 (4.3)               | 9.6 (3.2)           | <0.001    |
| Prothrombin (%)               | 86 (14)            | 94 (11)                  | 73 (13)             | <0.001    |
| Albumin (g/dL)                | 4.1 (0.4)          | 4.3 (0.3)                | 3.7 (0.5)           | <0.001    |
| Total bilirubin (mg/dL)       | 0.9 (0.4)          | 0.7 (0.2)                | 1.2 (0.7)           | <0.001    |
| AST (U/L)                     | 35 (16)            | 31 (13)                  | 42 (18)             | <0.001    |
| ALT (U/L)                     | 29 (17)            | 29 (17)                  | 30 (15)             | <0.001    |
| γ-GT (U/L)                    | 59 (52)            | 46 (38)                  | 80 (70)             | <0.001    |
| ALP (U/L)                     | 304 (108)          | 261 (77)                 | 370 (137)           | <0.001    |
| ChE (U/L)                     | 266 (76)           | 305 (61)                 | 206 (71)            | <0.001    |
| eGFR (mL/min/1.73 m²)         | 69.5 (15.2)        | 71.4 (13.3)              | 66.5 (17.7)         | <0.001    |
| Total cholesterol (mg/dL)     | 180 (30)           | 189 (28)                 | 163 (28)            | <0.001    |
| Ammonia (μg/dL)               | 46 (21)            | 35 (11)                  | 61 (28)             | <0.001    |
| BTR                           | 5.8 (1.5)          | 6.3 (1.2)                | 4.9 (1.8)           | <0.001    |
| HbA1c (%)                     | 5.9 (0.6)          | 5.9 (0.5)                | 6.0 (0.7)           | 0.121     |
| FIB-4                         | 4.2 (2.4)          | 2.7 (1.2)                | 6.8 (3.1)           | <0.001    |
| M2BPGi (COI)                  | 2.6 (2.1)          | 1.2 (0.6)                | 4.5 (3.2)           | <0.001    |
| Serum zinc levels (μg/dL)     | 67 (12)            | 72 (9)                   | 59 (13)             | <0.001    |
| Serum copper levels (μg/dL)   | 109 (19)           | 117 (19)                 | 91 (12)             | <0.001    |
| Serum iron levels (μg/dL)     | 106 (36)           | 106 (32)                 | 105 (41)            | 0.090     |
| Ferritin (ng/mL)              | 136 (112)          | 136 (105)                | 136 (120)           | 0.024     |

Categorical variables are expressed as number (%), and the continuous variables as the mean ± SD. Frequency comparisons between groups were analyzed using the χ²-test or Fisher’s exact test. Mean differences were evaluated by Mann–Whitney U-test.

†Eight patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection, six patients with autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) overlap syndrome, five patients with idiopathic portal hypertension, three patients with hepatic echinococcosis, two patients with primary sclerosing cholangitis, two patients with Wilson’s disease, two patients with extrahepatic portal venous obstruction, and one patient with hemochromatosis.

γ-GT, γ-glutamyltransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; BCAA, branched-chain amino acids; BTR, branched-chain amino acid and tyrosine ratio; BMI, body mass index; ChE, cholinesterase; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HCC, hepatocellular carcinoma; M2BPGi, Mac-2 binding protein glycosylation isomer; WBC, white blood cell.
A relationship has not been elucidated. In the present study, a DISCUSSION

When patients with a serum zinc level of < 60 μg/dL had an albumin level of < 3.0 g/dL (94.4%, n = 108), 132 had an albumin level of ≥ 3.0 to < 3.5 g/dL (88.6%, n = 149), 165 had an albumin level of ≥ 3.5 to < 4.0 g/dL (47.0%, n = 351), and 155 had an albumin level of ≥ 4.0 g/dL (11.4%, n = 1365). Of the 257 patients with an albumin level of < 3.5 g/dL, 234 (91.1%) had a serum zinc level of < 3.0 g/dL (Fig. 2).

Proportions of patients with serum zinc level < 60 μg/dL according to serum albumin levels

When patients with a serum zinc level of < 60 μg/dL were divided according to serum albumin levels, 102 patients had an albumin level of < 3.0 g/dL, 132 had an albumin level of ≥ 3.0 to < 3.5 g/dL, 165 had an albumin level of ≥ 3.5 to < 4.0 g/dL, and 155 had an albumin level of ≥ 4.0 g/dL. The similar measurement might be necessary when serum albumin levels are < 3.5 g/dL.

Among blood test parameters, serum zinc levels were moderately correlated with albumin, cholinesterase, M2BPGi, FIB-4 index, and hemoglobin levels. When only patients with cirrhosis were considered, these parameters showed even higher correlation coefficients. In particular, serum albumin levels are strongly correlated with serum zinc deficiency in patients with CLD

| Table 2 Correlation of serum zinc levels with blood test values and patients’ clinical characteristics |
|---------------------------------|-----------------|-----------------|-----------------|
| Overall | Non-cirrhosis | Cirrhosis |
|--------|----------------|-------------|
|        | r   | P-value | r   | P-value | r   | P-value |
| Albumin | 0.641 | <0.001 | 0.432 | <0.001 | 0.767 | <0.001 |
| ChE | 0.587 | <0.001 | 0.354 | <0.001 | 0.712 | <0.001 |
| M2BPGi | -0.490 | <0.001 | -0.158 | <0.001 | -0.647 | <0.001 |
| FIB-4 | -0.430 | <0.001 | -0.153 | <0.001 | -0.436 | <0.001 |
| Hemoglobin | 0.414 | <0.001 | 0.244 | <0.001 | 0.465 | <0.001 |
| Total cholesterol | 0.399 | <0.001 | 0.273 | <0.001 | 0.420 | <0.001 |
| Prothrombin | 0.389 | <0.001 | 0.073 | 0.19 | 0.451 | <0.001 |
| Ammonia | -0.386 | <0.001 | -0.099 | 0.006 | -0.406 | <0.001 |
| BTR | 0.376 | <0.001 | 0.205 | <0.001 | 0.377 | <0.001 |
| Platelet | 0.331 | <0.001 | 0.055 | 0.055 | 0.252 | <0.001 |
| ALP | -0.328 | <0.001 | -0.132 | <0.001 | -0.392 | <0.001 |
| AST | -0.242 | <0.001 | -0.044 | 0.127 | -0.278 | <0.001 |
| Age | -0.200 | <0.001 | -0.144 | <0.001 | -0.097 | 0.008 |
| WBC | 0.164 | <0.001 | 0.004 | 0.878 | 0.154 | <0.001 |
| eGFR | 0.154 | <0.001 | 0.097 | 0.004 | 0.113 | 0.006 |
| Fe | 0.134 | <0.001 | 0.167 | <0.001 | 0.065 | 0.115 |
| Ferritin | 0.114 | <0.001 | 0.144 | <0.001 | 0.041 | 0.342 |
| Total bilirubin | -0.105 | <0.001 | 0.186 | <0.001 | -0.279 | <0.001 |
| BMI | 0.087 | 0.001 | 0.132 | <0.001 | 0.121 | 0.002 |
| γ-GT | -0.068 | 0.003 | 0.042 | 0.147 | 0.030 | 0.408 |
| HbA1c | 0.020 | 0.510 | 0.005 | 0.899 | 0.091 | 0.080 |
| ALT | -0.015 | 0.498 | 0.092 | 0.001 | -0.035 | 0.340 |
| Cu | -0.010 | 0.712 | -0.012 | 0.695 | 0.015 | 0.725 |

Spearman’s rank correlation coefficient analysis was used to evaluate relationships between serum zinc levels and blood test values and patients’ clinical characteristics. γ-GT, γ-glutamyltransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BTR, branched-chain amino acid and tyrosine ratio; ChE, cholinesterase; Cu, copper; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; M2BPGi, Mac-2 binding protein glycosylation isomer; WBC, white blood cell.
The limitations of the present study were that the serum zinc levels show circadian variations, are high in the early morning, and decrease toward the afternoon. Therefore, blood sample collection should preferably be carried out in the early morning when patients have fasted. However, because of the difficulty in collecting samples at the same time from all patients in a clinical setting, this study did not define a fixed sampling time.

Historically, there were no zinc preparations approved for the treatment of hypozincemia in Japan. However, in March 2017, zinc acetate hydrate was approved for the additional indication of hypozincemia. Recently, it was reported that hypozincemia was associated with developing HCC in hepatitis C virus-related cirrhosis. Because the long-term administration of zinc to patients with CLD with zinc deficiency was reported to prevent worsening of liver function and progression of hepatic fibrosis, and to reduce the risk of developing HCC, zinc supplementation with zinc acetate hydrate might not only relieve various symptoms associated with zinc deficiency, but can also improve the quality of life and prognosis in patients with CLD. We hope that the present study will be helpful for better understanding zinc deficiency associated with CLDs.

ACKNOWLEDGMENTS

N ONE.

REFERENCES

1. Prasad AS. Zinc an overview. Nutrition 1995; 11: 93–9.
2. Pabo CO, Peisach E, Grant RA. Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem 2001; 70: 313–40.
3. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000; 102: 549–52.
4. Kadmon JL, Bechkerie MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 2004; 5: 920–31.
5. World Health Report 2002. Reducing Risks Promoting Health Life. Geneva: 2002; 10–250.
6. Wessells KR, Brown KH. Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS ONE 2012; 7: e50568. https://doi.org/10.1371/journal.pone.0050568.
7. Yanagisawa H. Zinc deficiency and clinical practice. JMAJ 2004; 47: 359–64.
8. Stamoulis I, Kouraklis G, Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci 2007; 52: 1595–612.
9. Grüngeff K, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. Ann Hepatol 2016; 15: 7–16.
10 Himoto T, Masaki T. Associations between Zinc Deficiency and Metabolic Abnormalities in Patients with Chronic Liver Disease. *Nutrients* 2018; 10(1): E88. https://doi.org/10.3390/nu10010088.

11 Chalasani N, Younossi ZM, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012; 55: 2005–23.

12 Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 2005; 41: 48–54.

13 Kodama H, Itakura H, Ohmori H et al. Practice Guideline for Zinc Deficiency. *Jpn Soc Clin Nutr* 2016; 38: 104–48 (in Japanese).

14 Katayama K, Kawaguchi T, Shiraishi K et al. The prevalence and implication of zinc deficiency in patients with chronic liver disease. *J Clin Med Res* 2018; 10: 437–44.

15 Adeniyi FA, Heaton FW. The effect of zinc deficiency on alkaline phosphatase (EC3.1.3.1) and its isoenzymes. *Br J Nutr* 1980; 43: 561–9.

16 Weismann K, Høyer H. Serum alkaline phosphatase and serum zinc levels in the diagnosis and exclusion of zinc deficiency in man. *Am J Clin Nutr* 1985; 41: 1214–9.

17 Hambidge KM, Goodall MJ, Stall C, Pritts J. Post-prandial and daily changes in plasma zinc. *J Trace Elem Electrolytes Health Dis* 1989; 3: 55–7.

18 Kanabrochi EL, Sothern RB, Ryan MD et al. Circadian characteristics of serum calcium, magnesium and eight trace elements and of their metallo-moieties in urine of healthy middle-aged men. *Clin Ter* 2008; 159: 329–46.

19 Katayama K, Hosui A, Sakai Y et al. Effects of Zinc Acetate on Serum Zinc Concentrations in Chronic Liver Diseases: a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial and a Dose Adjustment Trial. *Biol Trace Elem Res* 2019 Aug 7. https://doi.org/10.1007/s12011-019-01851-y.

20 Shigefuku R, Iwasa M, Katayama K et al. Hypozincemia is associated with human hepatocarcinogenesis in hepatitis C virus-related liver cirrhosis. *Hepatol Res* 2019 Jun 25. https://doi.org/10.1111/hepr.13388.

21 Matsumura H, Nirei K, Nakamura H et al. Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. *J Clin Biochem Nutr* 2012; 51: 178–84.

22 Hosui A, Kimura E, Abe S et al. Long-term zinc supplementation improves liver function and decreases the risk of developing hepatocellular carcinoma. *Nutrients* 2018; 10: 1955. https://doi.org/10.3390/nu10121955.